JY
CRNX icon

Jeff Yass’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jeff Yass’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
35,192
-11,061
-24% -$411K ﹤0.01% 7492
2026
Q1 		$1.68M Buy
46,253
+12,742
+38% +$569K ﹤0.01% 6575
2025
Q4 		$1.56M Sell
33,511
-223,994
-87% -$9.97M ﹤0.01% 6155
2025
Q3 		$10.7M Buy
257,505
+129,841
+102% +$4.15M ﹤0.01% 2952
2025
Q2 		$3.67M Sell
127,664
-10,371
-8% -$320K ﹤0.01% 4560
2025
Q1 		$4.63M Buy
138,035
+87,784
+175% +$3.28M ﹤0.01% 3790
2024
Q4 		$2.57M Buy
50,251
+436
+0.9% +$24.4K ﹤0.01% 4763
2024
Q3 		$2.55M Buy
49,815
+13,955
+39% +$720K ﹤0.01% 4826
2024
Q2 		$1.61M Sell
35,860
-14,422
-29% -$666K ﹤0.01% 5522
2024
Q1 		$2.35M Buy
50,282
+26,600
+112% +$1.04M ﹤0.01% 4977
2023
Q4 		$843K Sell
23,682
-51,461
-68% -$1.58M ﹤0.01% 7399
2023
Q3 		$2.23M Buy
75,143
+47,716
+174% +$983K ﹤0.01% 4910
2023
Q2 		$494K Sell
27,427
-34,560
-56% -$689K ﹤0.01% 8345
2023
Q1 		$996K Buy
61,987
+51,752
+506% +$958K ﹤0.01% 6831
2022
Q4 		$187K Sell
10,235
-26,062
-72% -$459K ﹤0.01% 10229
2022
Q3 		$713K Buy
36,297
+23,628
+187% +$482K ﹤0.01% 7514
2022
Q2 		$236K Sell
12,669
-65,238
-84% -$1.3M ﹤0.01% 10209
2022
Q1 		$1.71M Buy
77,907
+30,991
+66% +$627K ﹤0.01% 5826
2021
Q4 		$1.33M Buy
46,916
+31,869
+212% +$786K ﹤0.01% 6505
2021
Q3 		$317K Buy
+15,047
New +$315K ﹤0.01% 10479

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return

Jeff Yass's CRNX Position: Q2 2026 in Review

Jeff Yass reduced its Crinetics Pharmaceuticals (CRNX) stake by 24% in Q2 2026, selling an estimated $411K and leaving 35,192 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7492.

Jeff Yass first reported a position in CRNX in Q3 2021 and has held it in 20 quarters since. The position peaked at $10.7M in Q3 2025. 265 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Jeff Yass held 35,192 shares of Crinetics Pharmaceuticals worth $1.32M as of Q2 2026.
  • Jeff Yass sold 11,061 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $411K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7492 holding.
  • Jeff Yass first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Jeff Yass's Crinetics Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 265 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.